Voyager Therapeutics Inc is a pioneering company dedicated to developing transformative gene therapies for severe neurological diseases. With a strong commitment to patients, Voyager Therapeutics strives to deliver innovative treatments that can significantly improve their quality of life. The company's corporate philosophy is centered around integrity, innovation, and collaboration. By combining cutting-edge science, advanced technologies, and a multidisciplinary approach, Voyager Therapeutics aims to unlock the potential of gene therapy and create new opportunities for patients suffering from neurological disorders. Through their unwavering dedication and expertise, Voyager Therapeutics is poised to revolutionize the field of gene therapy and address unmet medical needs.

Voyager Therapeutics Inc is primarily present in the United States.

Voyager Therapeutics Inc has achieved significant milestones in the field of gene therapy. The company has successfully developed and advanced several programs aimed at treating severe neurological diseases. One notable accomplishment includes the initiation of a phase 2 clinical trial for VY-AADC, a potential treatment for Parkinson's disease. Voyager also entered into a collaboration with AbbVie to develop gene therapies for Alzheimer's disease, tauopathies, and severe neurological diseases. Additionally, Voyager has forged partnerships with leading academic institutions and organizations, further solidifying its position as a prominent player in the field of gene therapy.

Voyager Therapeutics Inc is a biopharmaceutical company focused on developing gene therapies for severe neurological diseases. Founded in 2013, the company aims to address the significant unmet need in the field of neurodegenerative disorders. Voyager Therapeutics leverages its expertise in gene therapy to deliver transformative treatments for diseases such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The company collaborates with renowned institutions and has a robust pipeline of potential therapies. With a commitment to improving patients' lives, Voyager Therapeutics continues to make advancements in the field of gene therapy and neurology.

The main competitors of Voyager Therapeutics Inc in the market include companies such as Axovant Gene Therapies Ltd, uniQure N.V., and Solid Biosciences Inc.

Voyager Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Voyager Therapeutics Inc. focuses on developing gene therapies for severe neurological diseases. By harnessing the power of the central nervous system's ability to produce proteins, Voyager aims to address genetic deficiencies that cause these diseases. The company utilizes viral vectors to deliver therapeutic genes to the targeted areas of the brain, aiming to provide long-term benefits to patients. Voyager's expertise lies in the development of innovative treatments for Parkinson's disease, Huntington's disease, and other genetic disorders. Through its gene therapy platform, Voyager Therapeutics Inc. strives to improve the lives of individuals living with these debilitating conditions.

Voyager Therapeutics의 P/E 비율은 -3.87입니다.

Voyager Therapeutics의 P/S 비율은 6.54입니다.

Voyager Therapeutics에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 Voyager Therapeutics 매출은 49.48 백만 USD입니다.

예상되는 Voyager Therapeutics 이익은 -83.51 백만 USD입니다.

Voyager Therapeutics Inc. is a gene therapy company focused on developing therapies for genetic diseases. The company's business model is based on the development and commercialization of gene therapies for severe and rare diseases. By focusing on gene therapy, the company is aligned with developing effective treatments and enjoys a competitive advantage as the gene therapy market is still relatively new. Voyager Therapeutics has three types of gene therapies in its pipeline, including adeno-associated virus (AAV) gene therapies, ex-vivo gene therapies, and therapies for neurodegenerative diseases. In addition to developing therapies, the company also offers services such as clinical trials and gene therapy production. Voyager Therapeutics aims to make gene therapy the standard for treating severe diseases and plans to expand into other industries through licensing its technology and collaborating with other companies. The company has partnerships with major biotech and pharmaceutical companies to access resources and improve its scientific and technical capabilities. Overall, Voyager Therapeutics' business model aims to develop and market gene therapies to address unmet medical needs in rare and severe diseases, while also expanding its presence in other industries.

Voyager Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Voyager Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Voyager Therapeutics의 ISIN은 US92915B1061입니다.

Voyager Therapeutics의 WKN은 A143XJ입니다.

Voyager Therapeutics의 티커는 VYGR입니다.

지난 12개월 동안 Voyager Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Voyager Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Voyager Therapeutics의 현재 배당 수익률은 입니다.

Voyager Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Voyager Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Voyager Therapeutics은 '건강' 섹터에 속합니다.

Voyager Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Voyager Therapeutics는 0 USD를 배당금으로 지급했습니다.

Voyager Therapeutics의 배당금은 USD에 지급됩니다.